Lineage Cell Therapeutics Q3 EPS $(0.13) Misses $(0.02) Estimate, Sales $3.681M Beat $2.300M Estimate
Benzinga Newsdesk 12 months ago
EarningsEarnings BeatsEarnings MissesNews
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.02) by 441.67 percent. This is a 550 percent decrease over losses of $(0.02) per
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.02) by 441.67 percent. This is a 550 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $3.681 million which beat the analyst consensus estimate of $2.300 million by 60.02 percent. This is a 2.59 percent decrease over sales of $3.779 million the same period last year.